Mr. Ken d'Entremont reports

MEDEXUS SCHEDULES THIRD FISCAL QUARTER 2024 CONFERENCE CALL

Medexus Pharmaceuticals Inc. plans to host a conference call at 8 a.m. Eastern Time on Thursday, Feb. 8, 2024, to discuss Medexus's results for its third fiscal quarter ended Dec. 31, 2023. Medexus expects to file its financial statements and management's discussion and analysis after markets close on Feb. 7, 2024.

To participate in the call, please dial the following numbers:

• 888-506-0062 (toll-free) for Canadian and U.S. callers;
• 1-973-528-0011 for international callers;
• Access code: 913043.

A live webcast of the call will be available on the investors section of Medexus's corporate website.

A replay of the call will be available approximately one hour following the end of the call through Thursday, Feb. 15, 2024. To access the replay, please dial the following numbers:

• 877-481-4010 for Canadian and U.S. callers;
• 1-919-882-2331 for international callers;
• Conference ID: 49777.

A replay of the webcast will be available on the investors section of Medexus's corporate website until Saturday, Feb. 8, 2025.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology.

We seek Safe Harbor.